Pancreatic Cancer Research

ResearcherUniversity of PittsburghNo recent work listed

Selwyn Maurice Vickers

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3133-5543; OpenAlex author ID A5072799975; NIH RePORTER profile ID 1859732. Sources: OpenAlex.

Their work

Papers
31 (first author 0, last author 2)
Trials
0
Grants
1
Labs led
1
Collaborators
81
Papers, trials and grants by year

2011: 5 papers · 2012: 4 papers · 2013: 5 papers · 2014: 3 papers, 1 grant · 2015: 3 papers · 2016: 3 papers · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: 4 papers · 2023: 1 paper

Papers 31

  1. Are Lymph Node Metastases Associated With Survival in Black Patients With Pancreatic Cancer? Co-author DOI 10.1016/j.jss.2022.11.031↗
  2. Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma? Co-author DOI 10.1016/j.amjsurg.2022.04.004↗
  3. Minnelide synergizes with conventional chemotherapy by targeting both cancer and associated stroma components in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215591↗
  4. Racial Disparity Between Whites and African Americans in Incidence and Outcome of Pancreatic Cancer: Have We Made a Difference? Co-author DOI 10.1053/j.gastro.2021.12.256↗
  5. The Fate of Resectable Pancreatic Adenocarcinoma After Neoadjuvant Chemotherapy. Co-author DOI 10.1097/mpa.0000000000001972↗
  6. O-GlcNAc modification of Sox2 regulates self-renewal in pancreatic cancer by promoting its stability. Co-author DOI 10.7150/thno.32615↗
  7. Inactivation of Cancer-Associated-Fibroblasts Disrupts Oncogenic Signaling in Pancreatic Cancer Cells and Promotes Its Regression. Co-author DOI 10.1158/0008-5472.can-17-2320↗
  8. Increased pancreatic cancer survival with greater lymph node retrieval in the National Cancer Data Base. Co-author DOI 10.1016/j.amjsurg.2017.06.036↗
  9. Pancreatic cancer survivors' preferences, barriers, and facilitators related to physical activity and diet interventions. Co-author DOI 10.1007/s11764-016-0544-5↗
  10. RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4. Co-author DOI 10.1016/j.molonc.2016.05.004↗
  11. Disposition of the Dietary Mutagen 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline in Healthy and Pancreatic Cancer Compromised Humans. Co-author DOI 10.1021/acs.chemrestox.5b00495↗
  12. Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer. Co-author DOI 10.1016/j.surg.2015.01.006↗
  13. Targeting Acidity in Pancreatic Adenocarcinoma: Multispectral Optoacoustic Tomography Detects pH-Low Insertion Peptide Probes In Vivo. Co-author DOI 10.1158/1078-0432.ccr-15-0314↗
  14. CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer. Co-author DOI 10.18632/oncotarget.3228↗
  15. Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway. Co-author DOI 10.1016/j.canlet.2014.03.016↗
  16. Triptolide activates unfolded protein response leading to chronic ER stress in pancreatic cancer cells. Co-author DOI 10.1152/ajpgi.00466.2013↗
  17. CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide. Co-author DOI 10.1158/1078-0432.ccr-13-2947↗
  18. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in… Co-author DOI 10.1002/cam4.137↗
  19. Intravenous genetic mesothelin vaccine based on human adenovirus 40 inhibits growth and metastasis of pancreatic cancer. Co-author DOI 10.1002/ijc.27983↗
  20. Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1. Co-author DOI 10.1074/jbc.m113.500983↗
  21. Triptolide induces the expression of miR-142-3p: a negative regulator of heat shock protein 70 and pancreatic cancer cell proliferation. Co-author DOI 10.1158/1535-7163.mct-12-1231↗
  22. miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death. Co-author DOI 10.1186/1476-4598-12-105↗
  23. Generation of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy. Co-author DOI 10.1016/j.amjsurg.2012.02.016↗
  24. Delivery of interferon alpha using a novel Cox2-controlled adenovirus for pancreatic cancer therapy. Last author DOI 10.1016/j.surg.2012.02.017↗
  25. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Co-author DOI 10.1126/scitranslmed.3004334↗
  26. MUC1c regulates cell survival in pancreatic cancer by preventing lysosomal permeabilization. Co-author DOI 10.1371/journal.pone.0043020↗
  27. A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally… Last author DOI 10.1007/s00280-010-1383-0↗
  28. Autoimmune pancreatitis mimicking pancreatic cancer. Co-author DOI 10.1007/s00534-010-0321-1↗
  29. Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Co-author DOI 10.1016/j.canlet.2011.05.002↗
  30. Serum biomarker panels for the detection of pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-10-0248↗
  31. Molecular targeted approaches for treatment of pancreatic cancer. Co-author DOI 10.2174/138161211796957427↗

Grants 1

  1. Biostatistics Core P50CA101955↗

Closest collaborators

The 25 strongest of 81 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Vikas Dudeja · 16 shared papers, 2011–2023 · strength 1.21
  2. Ashok Kumar Saluja · 15 shared papers, 2011–2022 · strength 0.88
  3. Sulagna Banerjee · 11 shared papers, 2012–2019 · strength 0.53
  4. Ahmer Irfan · 3 shared papers, 2022–2023 · strength 0.50
  5. John Bart Rose · 3 shared papers, 2022–2023 · strength 0.50
  6. Olumide B. Gbolahan · 3 shared papers, 2022–2023 · strength 0.50
  7. Vineet Kumar Gupta · 4 shared papers, 2018–2022 · strength 0.44
  8. Sushanth Reddy · 3 shared papers, 2017–2023 · strength 0.40
  9. Hua Amanda Fang · 2 shared papers, 2022–2023 · strength 0.32
  10. Nikita Sharma · 3 shared papers, 2018–2022 · strength 0.31
  11. Somnath Pandey · 2 shared papers, 2022 · strength 0.28
  12. Shrey Modi · 2 shared papers, 2022 · strength 0.28
  13. Shweta Lavania · 2 shared papers, 2022 · strength 0.28
  14. Masato Yamamoto · 6 shared papers, 2012–2015 · strength 0.26
  15. Rohit Chugh · 6 shared papers, 2012–2015 · strength 0.26
  16. Bhuwan Giri · 2 shared papers, 2019–2022 · strength 0.24
  17. Donald J Buchsbaum · 3 shared papers, 1 shared grant, 2011–2016 · strength 0.21
  18. Sushanth Reddy · 1 shared paper, 2022 · strength 0.17
  19. Julia Davydova · 4 shared papers, 2012–2015 · strength 0.17
  20. Kousik Kesh · 2 shared papers, 2018–2019 · strength 0.16
  21. Patricia Dauer · 2 shared papers, 2018–2019 · strength 0.16
  22. John D. Christein · 4 shared papers, 2011–2016 · strength 0.15
  23. Vrishketan Sethi · 1 shared paper, 2022 · strength 0.15
  24. Seifeldin Awad · 1 shared paper, 2022 · strength 0.15
  25. Carlo M. Contreras · 2 shared papers, 2016–2017 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.